Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://jasonyueo604366.blogrelation.com/49499875/this-new-drug-retatrutide-australia-a-potential-solution-for-obesity-treatment